Cargando…
Pharmacokinetics of ferric bepectate—a new intravenous iron drug for treating iron deficiency
IV iron is indicated in clinical conditions, where rapid anaemia alleviation and repletion of iron stores are required. The acute toxicity of IV iron is ascribed to the presence of labile iron in plasma. Thus, shorter plasma residence time might improve the safety profile, even for compounds holding...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6849879/ https://www.ncbi.nlm.nih.gov/pubmed/30839153 http://dx.doi.org/10.1111/bcpt.13219 |
_version_ | 1783469300211777536 |
---|---|
author | Muñoz, Manuel Olsen, Peter Skov Petersen, Tonny Studsgaard Manhart, Susanne Waldorff, Stig |
author_facet | Muñoz, Manuel Olsen, Peter Skov Petersen, Tonny Studsgaard Manhart, Susanne Waldorff, Stig |
author_sort | Muñoz, Manuel |
collection | PubMed |
description | IV iron is indicated in clinical conditions, where rapid anaemia alleviation and repletion of iron stores are required. The acute toxicity of IV iron is ascribed to the presence of labile iron in plasma. Thus, shorter plasma residence time might improve the safety profile, even for compounds holding‐on the iron tightly. In this single‐centre, open‐label, single‐dose escalation study, we evaluated the elimination kinetics of ferric bepectate (FBP) compared to those of ferric carboxymaltose (FCM). Thirty‐three iron‐depleted anaemic patients who had undergone cardiac surgery were included and received 200, 500 or 1500 mg FBP or 500 mg FCM. Plasma drug curves were subjected to model‐free analysis. Because saturation kinetics was found, a compartmental model with limited elimination capacity was applied. Urinary iron excretion was also analysed. The initial non‐compartmental analysis revealed an increasing AUC/dose ratio for FBP. For both drugs, the central distribution compartment corresponded to plasma volume, and elimination followed Michaelis‐Menten saturation kinetics. Maximal elimination rates (V (max)) were 224 mg/h and 81 mg/h for FBP 500 mg and FCM 500 mg, respectively; drug concentrations at half V (max) (K (m)), 99 mg/L and 212 mg/L, respectively; and terminal plasma half‐life (T½), 3.05 h and 8.96 h, respectively. Both drugs were equally effective in eliciting an early ferritin rise. Urinary iron excretion was measurable in all patients receiving FCM but not in those receiving FBP, which was well tolerated. Intravenous iron drugs are subject to capacity‐limited elimination with different saturation thresholds. Urinary iron excretion can be used as a surrogate for labile plasma iron. |
format | Online Article Text |
id | pubmed-6849879 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-68498792019-11-15 Pharmacokinetics of ferric bepectate—a new intravenous iron drug for treating iron deficiency Muñoz, Manuel Olsen, Peter Skov Petersen, Tonny Studsgaard Manhart, Susanne Waldorff, Stig Basic Clin Pharmacol Toxicol ORIGINAL ARTICLES IV iron is indicated in clinical conditions, where rapid anaemia alleviation and repletion of iron stores are required. The acute toxicity of IV iron is ascribed to the presence of labile iron in plasma. Thus, shorter plasma residence time might improve the safety profile, even for compounds holding‐on the iron tightly. In this single‐centre, open‐label, single‐dose escalation study, we evaluated the elimination kinetics of ferric bepectate (FBP) compared to those of ferric carboxymaltose (FCM). Thirty‐three iron‐depleted anaemic patients who had undergone cardiac surgery were included and received 200, 500 or 1500 mg FBP or 500 mg FCM. Plasma drug curves were subjected to model‐free analysis. Because saturation kinetics was found, a compartmental model with limited elimination capacity was applied. Urinary iron excretion was also analysed. The initial non‐compartmental analysis revealed an increasing AUC/dose ratio for FBP. For both drugs, the central distribution compartment corresponded to plasma volume, and elimination followed Michaelis‐Menten saturation kinetics. Maximal elimination rates (V (max)) were 224 mg/h and 81 mg/h for FBP 500 mg and FCM 500 mg, respectively; drug concentrations at half V (max) (K (m)), 99 mg/L and 212 mg/L, respectively; and terminal plasma half‐life (T½), 3.05 h and 8.96 h, respectively. Both drugs were equally effective in eliciting an early ferritin rise. Urinary iron excretion was measurable in all patients receiving FCM but not in those receiving FBP, which was well tolerated. Intravenous iron drugs are subject to capacity‐limited elimination with different saturation thresholds. Urinary iron excretion can be used as a surrogate for labile plasma iron. John Wiley and Sons Inc. 2019-04-03 2019-08 /pmc/articles/PMC6849879/ /pubmed/30839153 http://dx.doi.org/10.1111/bcpt.13219 Text en © 2019 The Authors. Basic & Clinical Pharmacology & Toxicology published by John Wiley & Sons Ltd on behalf of Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society). This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | ORIGINAL ARTICLES Muñoz, Manuel Olsen, Peter Skov Petersen, Tonny Studsgaard Manhart, Susanne Waldorff, Stig Pharmacokinetics of ferric bepectate—a new intravenous iron drug for treating iron deficiency |
title | Pharmacokinetics of ferric bepectate—a new intravenous iron drug for treating iron deficiency |
title_full | Pharmacokinetics of ferric bepectate—a new intravenous iron drug for treating iron deficiency |
title_fullStr | Pharmacokinetics of ferric bepectate—a new intravenous iron drug for treating iron deficiency |
title_full_unstemmed | Pharmacokinetics of ferric bepectate—a new intravenous iron drug for treating iron deficiency |
title_short | Pharmacokinetics of ferric bepectate—a new intravenous iron drug for treating iron deficiency |
title_sort | pharmacokinetics of ferric bepectate—a new intravenous iron drug for treating iron deficiency |
topic | ORIGINAL ARTICLES |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6849879/ https://www.ncbi.nlm.nih.gov/pubmed/30839153 http://dx.doi.org/10.1111/bcpt.13219 |
work_keys_str_mv | AT munozmanuel pharmacokineticsofferricbepectateanewintravenousirondrugfortreatingirondeficiency AT olsenpeterskov pharmacokineticsofferricbepectateanewintravenousirondrugfortreatingirondeficiency AT petersentonnystudsgaard pharmacokineticsofferricbepectateanewintravenousirondrugfortreatingirondeficiency AT manhartsusanne pharmacokineticsofferricbepectateanewintravenousirondrugfortreatingirondeficiency AT waldorffstig pharmacokineticsofferricbepectateanewintravenousirondrugfortreatingirondeficiency |